prikaz prve stranice dokumenta Could the CCR5-Δ32 Mutation be Protective in SARS-CoV-2 Infection?
  Download
PDF 539.95 KB
Scientific paper - Preliminary note / Short communication
Could the CCR5-Δ32 Mutation be Protective in SARS-CoV-2 Infection?
Physiological research, 70 (2021), Suppl. 2; S249-S252. https://doi.org/10.33549/physiolres.934725
Starčević Čizmarević, Nada; Kapović, Miljenko; Rončević, Dobrica; Ristić, Smiljana

Linked objects
COVID-19 | Virtual collection

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Starčević Čizmarević, N., Kapović, M., Rončević, D. & Ristić, S. (2021). Could the CCR5-Δ32 Mutation be Protective in SARS-CoV-2 Infection?. Physiological research, 70. (Suppl. 2), S249-S252. doi: 10.33549/physiolres.934725

Starčević Čizmarević, Nada, et al. "Could the CCR5-Δ32 Mutation be Protective in SARS-CoV-2 Infection?." Physiological research, vol. 70, no. Suppl. 2, 2021, pp. S249-S252. https://doi.org/10.33549/physiolres.934725

Starčević Čizmarević, Nada, Miljenko Kapović, Dobrica Rončević and Smiljana Ristić. "Could the CCR5-Δ32 Mutation be Protective in SARS-CoV-2 Infection?." Physiological research 70, no. Suppl. 2 (2021): S249-S252. https://doi.org/10.33549/physiolres.934725

Starčević Čizmarević, N., et al. (2021) 'Could the CCR5-Δ32 Mutation be Protective in SARS-CoV-2 Infection?', Physiological research, 70(Suppl. 2), pp. S249-S252. doi: 10.33549/physiolres.934725

Starčević Čizmarević N, Kapović M, Rončević D, Ristić S. Could the CCR5-Δ32 Mutation be Protective in SARS-CoV-2 Infection?. Physiological research [Internet]. 2021 [cited 2024 April 27];70(Suppl. 2):S249-S252. doi: 10.33549/physiolres.934725

N. Starčević Čizmarević, M. Kapović, D. Rončević and S. Ristić, "Could the CCR5-Δ32 Mutation be Protective in SARS-CoV-2 Infection?", Physiological research, vol. 70, no. Suppl. 2, pp. S249-S252, 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:933486. [Accessed: 27 April 2024]

Metadata
Title (english)Could the CCR5-Δ32 Mutation be Protective in SARS-CoV-2 Infection?
Title (english)Could the CCR5-Δ32 Mutation be Protective in SARS-CoV-2 Infection?
AuthorNada Starčević Čizmarević
AuthorMiljenko Kapović
AuthorDobrica Rončević
AuthorSmiljana Ristić
MBZ: 142283
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Biology and Medical Genetics)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Abstract (english)
Increasing evidence points to host genetics as a factor in COVID-19 prevalence and outcome. CCR5 is a receptor for proinflammatory chemokines that are involved in host responses, especially to viruses. The CCR5 Δ32 minor allele is an interesting variant, given the role of CCR5 in some viral infections, particularly HIV-1. Recent studies of the impact of CCR5-Δ32 on COVID-19 risk and severity have yielded contradictory results. This ecologic study shows that the CCR5-Δ32 allelic frequency in a European population was significantly negatively correlated with the number of COVID-19 cases (p=0.035) and deaths (p=0.006) during the second pandemic wave. These results suggest that CCR5-Δ32 may be protective against SARS-CoV-2 infection, as it is against HIV infection, and could be predictive of COVID-19 risk and severity. Further studies based on samples from populations of different genetic backgrounds are needed to validate these statistically obtained findings.
Keywords (english)
Languageenglish
Publication typeScientific paper - Preliminary note / Short communication
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titlePhysiological research
Numberingvol. 70, no. Suppl. 2, pp. S249-S252
p-ISSN0862-8408
DOIhttps://doi.org/10.33549/physiolres.934725
URN:NBNurn:nbn:hr:184:933486
Publication2021
ProjectNumber: uniri-biomed-18-137
Title (croatian): Farmakogenetika multiple skleroze:odgovor na imunomodulacijsku terapiju
Title (english): Farmacogenetics of multiple sclerosis: response to disease-modifying therapy
Leader: Nada Starčević Čizmarević
Jurisdiction: Croatia
Funding stream: Sveučilište u Rijeci
Document URLhttp://bib.irb.hr/1166388
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2022-01-26 08:15:24